Would you consider use of single-agent lenvatinib for advanced renal cell cancer after first-line therapy?

Data reported by Motzer et al Lancet 2015 demonstrated a statistically superior PFS benefit of lenvatinib monotherapy over everolimus alone. In particular, would you consider lenvatinib monotherapy if patients were started on combination therapy and experienced toxicity attributable to everolimus?

Answer from: Medical Oncologist at Academic Institution

I have not used this combination because I feel more data is needed. Previous mTOR+VEGF combinations failed to improve outcomes when studied in large phase 3 trials, so I am a bit skeptical of these results and waiting for the phase 3 to ready out. In addition, there is significant toxicity wtih thi...

Comments

Medical Oncologist at Vanderbilt University Medical Center
If you can get access to checkpoint inhibitor in c...

Medical Oncologist at Sweetwater Regional Medical Center
@Brian I. Rini, could you expand on the question o...

Answer from: Medical Oncologist at Academic Institution

Monotherapy with lenvatinib is certainly active as seen in the phase 2 study so yes I think it is a reasonable choice. I agree TKI + I/O is active but would caution against doing this outside of a clinical trial.

Please select the option that best describes you:

Would you consider use of single-agent lenvatinib for advanced renal cell cancer after first-line therapy?

Related Questions